{
    "name": "trifluridine/tipiracil",
    "comment": "Rx",
    "other_names": [
        "Lonsurf"
    ],
    "classes": [
        "Thymidine Phosphorylase Inhibitors",
        "Thymidylate Synthetase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/lonsurf-trifluridine-tipiracil-1000021",
    "pregnancy": {
        "common": [
            "Based on animal data and its mechanism of action, drug can cause fetal harm",
            "Embryo-fetal lethality and embryo-fetal toxicity occurred in pregnant rats when given during gestation at doses resulting in exposures lower than or similar to human exposures at the recommended clinical dose",
            "There are no available data use in pregnant women",
            "Verify pregnancy status in females of reproductive potential before initiating treatment"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for ≥6 months after final dose",
                    "Males with female partners of reproductive potential: Use condoms during treatment and for ≥ 3 months after final dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of trifluridine, tipiracil or its metabolites in human milk or its effects on the breastfed child or on milk production",
            "In nursing rats, trifluridine and tipiracil or their metabolites were present in breast milk",
            "Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 1 day following the final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Severe and life-threatening myelosuppression reported, including anemia, neutropenia, thrombocytopenia, and febrile neutropenia; obtain CBC count prior to and on Day 15 of each cycle, or more frequently as indicated",
                "Stomatitis may occur",
                "Associated with a moderate emetic potential; antiemetics to prevent nausea and vomiting recommended; patient should report severe gastrointestinal toxicity to healthcare professional",
                "Grade 3 or 4 bilirubin elevations reported in patients with hepatic impairment",
                "Based on animal studies and its mechanism of action, trifluridine/tipiracil can cause fetal harm when administered to pregnant women (see Pregnancy)"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Stomatitis",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "4"
        },
        {
            "name": "or",
            "percent": null
        }
    ]
}